Indwara ziterwa na Autoimmune, zubwoko butandukanye kandi ahanini zikaba ari inzitizi nindwara zikomeye, nimwe mubyerekezo byingenzi byiterambere ryibiyobyabwenge.JAK-STAT ni imwe mu nzira nke zo gukingira indwara byagaragaye, cyane cyane JAK inhibitor.Ibiyobyabwenge byinshi,nka tofacitinib, byagurishijwe ku isi hose.

Intego ya JAK yatunganijwe mu gihe kitarenze imyaka 20, ariko kuri ubu amoko agera kuri 7 yemerewe kwamamaza.Ibimenyetso byerekana cyane cyane ibibyimba n'indwara zo kwirinda indwara, kandi ibindi bimenyetso binonosoye ni cyane cyane fibrosis yo mu magufa na rubagimpande ya rubagimpande.Ibikurikira byibanze kuri inhibitor ya JAK ya mbere (tofacitinib) yo kuvura rubagimpande ya rubagimpande.

Tofacitinib ni molekile ntoya yo mu kanwa JAK inhibitor yakozwe na Pfizer.Ifite amahitamo meza ya JAK.Mu Gushyingo 2012, FDA yo muri Amerika yemeje citrate ya tofacitinib yo kuvura methotrexate idahagije cyangwa itihanganira imiti.Iki gicuruzwa nicyo cyambere cya JAK inhibitor yemejwe na FDA yo kuvura rubagimpande ya rubagimpande.Kugeza ubu, usibye ibimenyetso byemejwe, tofacitinib iranageragezwa ku mikorere yayo muri ankylose spondylitis, atopic dermatitis, keratoconjunctivitis sicca n'indwara ya Crohn.Ku bijyanye no kugurisha ku isi, igurishwa rya buri mwaka rya tofacitinib muri 2017 ryarenze miliyari imwe y’amadolari y’Amerika, naho kugurisha buri mwaka muri 2019 bigeze kuri miliyari 2.242.

Inzira zitandukanye za syntetique zizagira ingaruka zikomeye kumusaruro nubwiza bwa APIs.Synthesis yacu ya tofacitinib citrate irinda inzira yemewe.Inzira yubukorikori isaba igiciro gito cyibikoresho fatizo, umusaruro mwinshi, umwanda umwe nubuziranenge birashobora kugenzurwa mugihe gikwiye, cyangwa birashobora gutegurwa nabakiriya.Rero udushoboze kugira inyungu zigaragara kumasoko.Kugeza ubu ubushobozi bwacu bushobora kuba 50 kg buri kwezi, na tofacitinib citrate imaze koherezwa muri Amerika, Mexico, Franch, Bangladesh, nibindi.